Literature DB >> 24295133

The problem with cyclophosphamide, doxorubicin, vincristine and prednisone for the treatment of peripheral T-cell lymphoma.

Roopesh Kansara1, Kerry J Savage.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24295133     DOI： 10.3109/10428194.2013.858154

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  3 in total

1.  Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.

Authors:  Owen A O'Connor; Steven Horwitz; Tamás Masszi; Achiel Van Hoof; Peter Brown; Jeannette Doorduijn; Georg Hess; Wojciech Jurczak; Poul Knoblauch; Shanta Chawla; Gajanan Bhat; Mi Rim Choi; Jan Walewski; Kerry Savage; Francine Foss; Lee F Allen; Andrei Shustov
Journal:  J Clin Oncol       Date:  2015-06-22       Impact factor: 44.544

2.  Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma.

Authors:  Patrick B Johnston; Amanda F Cashen; Petros G Nikolinakos; Anne W Beaven; Stefan Klaus Barta; Gajanan Bhat; Steven J Hasal; Sven De Vos; Yasuhiro Oki; Changchun Deng; Francine M Foss
Journal:  Exp Hematol Oncol       Date:  2021-02-18

3.  Proliferative, pro-inflammatory, and angiogenesis regulator gene expression profile defines prognosis in different histopathological subtypes of nodal peripheral T-cell lymphoma.

Authors:  Luís Alberto de Pádua Covas Lage; Débora Levy; Flávia Dias Xavier; Diego Cândido Reis; Renata de Oliveira Costa; Marianne Castro Gonçalves; Vanderson Rocha; Maria Cláudia Nogueira Zerbini; Juliana Pereira
Journal:  Oncotarget       Date:  2019-08-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.